• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

by jtcir-auto | May 16, 2022 | Press Releases

TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today...

Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

by jtcir-auto | May 16, 2022 | Press Releases

TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today...

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease

by jtcir-auto | May 12, 2022 | Press Releases

– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying (“AIM”) Biologicals as a potential therapeutic treatment option for...

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

by jtcir-auto | May 11, 2022 | Press Releases

– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, May 11, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS)...

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

by jtcir-auto | May 11, 2022 | Press Releases

– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, May 11, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS)...

Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists

by jtcir-auto | Apr 25, 2022 | Press Releases

– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease (“PD”), a neurodegenerative movement disorder TORONTO, ONTARIO, April 25, 2022 (GLOBE NEWSWIRE)...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow